nivolumab

NADIM II Trial: Nivolumab in Lung Cancer

Objective: To examine the pathological Complete Response defined as the absence of residual tumor in lung and lymph nodes comparing patients treated with chemo-immunotherapy versus chemotherapy alone. Inclusion Criteria: Exclusion Criteria: Participants: 86 Patients Treatment Groups: Primary Outcome: Secondary Outcomes: … Read More

COSMIC-313 Trial: Cabozantinib in Renal Cell Cancer

The COSMIC-313 Trial: A New Frontier in Renal-Cell Carcinoma Treatment In the landscape of oncology, renal-cell carcinoma stands as a formidable challenge, often presenting at advanced stages and with a dire need for effective treatments. Enter the COSMIC-313 Trial, a … Read More